Physical Causes of APSD Changes in Aerosols from OIPs and Their Impact on CI Measurements - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 79

82. US Federal Drug Administration (2009) Guidance for industry: Q8(R2) pharmaceutical
development. Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/ucm073507.pdf . Accessed 8 May 2012
83. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd
MJ, Mitchell JP, Hochrainer D (2003) Next generation pharmaceutical impactor. Part 1:
Design. J Aerosol Med 16(3):283-299
84. Mitchell JP, Nagel MW (1999) Time-of-flight aerodynamic particle size analyzers: their use
and limitations for the evaluation of medical aerosols. J Aerosol Med 12(4):217-240
85. Roberts DL (2009) Theory of multi-nozzle impactor stages and the interpretation of stage
mensuration data. Aerosol Sci Technol 43(11):1119-1129
86. Chambers F, Aziz A, Mitchell J, Shelton C, Nichols C (2010) Cascade impactor (CI) mensura-
tion: an assessment of the accuracy and precision of commercially available optical measure-
ment systems. AAPS PharmSciTech 11(1):472-484
87. US Food and Drug Administration (FDA) (1998) CDER. Draft guidance for industry metered
dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and
controls documentation, Rockville, MD. http://www.fda.gov/cder/guidance/2180dft.pdf .
Accessed 6 Jan 2012